Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hemispherx Biopharma Inc.

Division of HemispheRx Biopharma Inc.
www.hemispherx.net

Latest From Micromet Inc.

Finance Watch: Bicycle Spins Toward Clinic With $52m Round; Stock Spikes Spur Offerings

Bicycle closes a $52m Series B to test its bicyclic peptides in humans, while Decipera, Harpoon and TP Therapeutics also top a $263m list of recent venture capital deals. In public company financings, Alnylam, Aerie and others price offerings to raise cash while their stocks are on the rise.

Financing Business Strategies

Ex-Sanofi Exec Stoeckli Primes Glenmark’s Cancer Therapy Ambitions

Glenmark’s president and chief scientific officer, Dr Kurt Stoeckli, believes that some big pharma companies may have missed the opportunity to embark on immunotherapy cancer treatment R&D “at the right time” and tells Scrip that there is room for the Indian firm to provide competitive assets in the space. Stoeckli, an ex-Sanofi senior executive, also outlines why the upside potential of Glenmark’s BEAT antibody technology platform is “remarkable”.

Research & Development ImmunoOncology

Amgen's Cancer Strategy: A Multitude Of Modalities In Immuno-Oncology And Beyond

Amgen is the leader in approved bispecific antibodies and oncolytic viruses, but the company's not shy about expanding its oncology pipeline with even more modes of delivering medicines to cancer patients.

Cancer Clinical Trials

Deal Watch: Amgen BiTEs Back Micromet-Developed Boehringer Antibody

Cancer immunotherapy biotech Leap, backed by HealthCare Ventures and Lilly, reverse-merges with Israel's Macrocure. Elite and SunGen will partner to develop generic versions of four drugs that posted $3bn in aggregate sales over a recent 12-month stretch.

Deals Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Immune Disorders
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • HemispheRx Biopharma Inc.
  • Senior Management
  • Thomas Equels, Pres. & CEO
    Adam Pascale, CFO
    David R Strayer, MD, CSO & CMO
    Wayne Springate, SVP, Ops
  • Contact Info
  • Hemispherx Biopharma Inc.
    Phone: (215) 988-0080
    One Penn Ctr., 1617 JFK Blvd.
    Suite 500
    Philadelphia, PA 19103
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register